Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,968 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
Ansell SM, Radford J, Connors JM, Długosz-Danecka M, Kim WS, Gallamini A, Ramchandren R, Friedberg JW, Advani R, Hutchings M, Evens AM, Smolewski P, Savage KJ, Bartlett NL, Eom HS, Abramson JS, Dong C, Campana F, Fenton K, Puhlmann M, Straus DJ; ECHELON-1 Study Group. Ansell SM, et al. Among authors: dong c. N Engl J Med. 2022 Jul 28;387(4):310-320. doi: 10.1056/NEJMoa2206125. Epub 2022 Jul 13. N Engl J Med. 2022. PMID: 35830649 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 36164033
Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1.
Crosswell HE, LaCasce AS, Bartlett NL, Straus DJ, Savage KJ, Zinzani PL, Collins GP, Fanale M, Fenton K, Dong C, Miao H, Grigg AP. Crosswell HE, et al. Among authors: dong c. Haematologica. 2024 Mar 1;109(3):982-987. doi: 10.3324/haematol.2023.283303. Haematologica. 2024. PMID: 37794803 Free PMC article. No abstract available.
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
Zhou X, Vaishampayan U, Mahalingam D, Harvey RD, Chung KY, Sedarati F, Dong C, Faller DV, Venkatakrishnan K, Gupta N. Zhou X, et al. Among authors: dong c. Invest New Drugs. 2022 Oct;40(5):1042-1050. doi: 10.1007/s10637-022-01286-8. Epub 2022 Aug 6. Invest New Drugs. 2022. PMID: 35932388 Free PMC article. Clinical Trial.
A chemical probe to modulate human GID4 Pro/N-degron interactions.
Owens DDG, Maitland MER, Khalili Yazdi A, Song X, Reber V, Schwalm MP, Machado RAC, Bauer N, Wang X, Szewczyk MM, Dong C, Dong A, Loppnau P, Calabrese MF, Dowling MS, Lee J, Montgomery JI, O'Connell TN, Subramanyam C, Wang F, Adamson EC, Schapira M, Gstaiger M, Knapp S, Vedadi M, Min J, Lajoie GA, Barsyte-Lovejoy D, Owen DR, Schild-Poulter C, Arrowsmith CH. Owens DDG, et al. Among authors: dong c. Nat Chem Biol. 2024 May 21. doi: 10.1038/s41589-024-01618-0. Online ahead of print. Nat Chem Biol. 2024. PMID: 38773330
[Clinical diagnostic practices for Chinese developmental dyslexia].
Liu ZL, Huo YY, Chen YN, Chi X, Zhang YY, Dong CF, Wu D, Liu SY, Zhu J, Chen JJ. Liu ZL, et al. Among authors: dong cf. Zhonghua Er Ke Za Zhi. 2024 May 15;62(6):548-552. doi: 10.3760/cma.j.cn112140-20240221-00114. Online ahead of print. Zhonghua Er Ke Za Zhi. 2024. PMID: 38763877 Chinese.
6,968 results